Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 19, 2007

Profectus BioSciences Receives NIH Grant to Enhance Anti-HIV Therapies

  • Profectus BioSciences won approximately $200,000 through a phase 1 SBIR grant from the NIAID. The company will use the funding to advance development of anti-HIV antibodies based on its AIM (antiviral immune modulation) therapy technology. The work will be conducted in collaboration with the Institute of Human Virology at the University of Maryland.

    AIM uses immune modulation drugs such as Rapamycin to improve the activity of antiviral antibodies, the company explains. “We believe that AIM therapy combinations can improve patient outcomes by providing less frequent dosing with fewer side effects and by slowing or preventing drug-resistant viruses that can drive treatment failure,” says Joseph F. Berardino, chairman and CEO. “Such an approach may also provide treatment options that permit intervention soon after infection.”

    Profectus BioSciences reports that this is the second phase 1 SBIR grant it has received in the past month.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »